Wellinks Adds Douglas Wenners to Board of Directors

Wenners Brings 25 Years of Health Plan Experience in Growth, Strategy, and Innovation

NEW HAVEN, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) — Wellinks, the leading digital healthcare company offering virtual Chronic Obstructive Pulmonary Disease (COPD) management for health plans and value-based care providers, today announced Douglas Wenners has joined its board of directors as an independent director. Wenners brings over 25 years of experience working with health plans, and he is a strong advocate for home-based care for people living with serious illnesses.

Prior to his current role, Wenners served as the CEO and co-founder of Prospero Health, a home-based medical care provider. Previously, he served as the CEO of Privia Health and significantly grew the company’s market presence by more than 25 percent. He also held various executive leadership positions at Anthem, where he designed the largest pay for value program in the country and redesigned the company’s public exchange business after the passage of the Affordable Care Act.

“COPD is the third leading cause of death by chronic disease in the United States, but there’s a lot of potential to keep people healthy at home,” said Alex Waldron, Wellinks CEO. “Doug’s skills and experience will accelerate our ability to fulfill our mission of helping people with COPD live fully and breathe freely.”

“COPD is a uniquely challenging issue to manage, but Wellinks has fundamentally changed the ability to engage this population,” said Wenners. “I look forward to working with more payers and providers across the country to bring more value and improve outcomes for those with COPD.”

Wellinks’ Board of Directors is chaired by HighCape Capital’s Kevin Rakin, and also includes Morningside’s Stephen Bruso, Laniakea and OTV’s Henry Weinstein, and Wellinks’ CEO Alex Waldron.

About Wellinks
Wellinks is on a mission to help those with chronic obstructive pulmonary disease (COPD) live fully and breathe freely. COPD is the third leading cause of death by chronic disease in the U.S. and the fifth most costly chronic disease. With its personalized, virtual-first COPD management system, Wellinks breaks down barriers for patients, providing the evidence-based care they need and deserve outside the four walls of the clinic. Wellinks supports patients through virtual care, including pulmonary rehabilitation, health coaching, and monitoring aided by connected devices and an easy-to-use smartphone app. Based in New Haven, Connecticut, Wellinks is led by a team of digital health veterans and backed by top investment firms including Morningside, HighCape Capital, Connecticut Innovations, and Benslie. For more information, visit www.wellinks.com and follow on Twitter (@WellinksHealth) and LinkedIn.

Press Contact:
Caitlin Krutsick
wellinks@crosscutstrategies.com

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

35 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

12 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

15 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

15 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

15 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

15 hours ago